20 Grants
2023
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer
Fishel, Melissa L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA282478-01), $466,315USD, 2023-08-01 -- 2028-07-31
2022
Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor Microenvironment
FLICK, MATTHEW J⋅Fishel, Melissa L and Han, Bumsoo
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1U01CA274304-01), $956,721USD, 2022-09-01 -- 2027-08-31
2021
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
FISHEL, MELISSA L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA167291-09), $493,726USD, 2013-01-01 -- 2023-02-28
 
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitors
FISHEL, MELISSA L and Han, Bumsoo
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA254110-01A1), $448,088USD, 2021-06-01 -- 2026-05-31
 
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis
FISHEL, MELISSA L⋅FLICK, MATTHEW J⋅Han, Bumsoo and Wolberg, Alisa S
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 5U01HL143403-04), $844,766USD, 2018-08-01 -- 2023-07-31
2020
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
FISHEL, MELISSA L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA167291-08), $493,726USD, 2013-01-01 -- 2023-02-28
 
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis
FISHEL, MELISSA L⋅FLICK, MATTHEW J⋅Han, Bumsoo and Wolberg, Alisa S
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 5U01HL143403-03), $855,078USD, 2018-08-01 -- 2023-07-31
2019
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
FISHEL, MELISSA L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA167291-07), $563,735USD, 01/01/2013 -- 02/28/2023
 
Exploring a Novel Signaling Node for Therapeutic Efficacy in MPNST
Fishel, Melissa
U.S. Department Of Defense (Dod) (ID: W81XWH1910217), $154,047USD, 6/1/2019 -- 5/31/2021
 
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis
FISHEL, MELISSA L⋅FLICK, MATTHEW J⋅Han, Bumsoo and Wolberg, Alisa S
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 7U01HL143403-02), $892,860USD, 08/01/2018 -- 07/31/2023
2018
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
FISHEL, MELISSA L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA167291-06S1), $227,554USD, 03/09/2018 -- 02/28/2020
 
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
FISHEL, MELISSA L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 2R01CA167291-06), $493,726USD, 01/01/2013 -- 02/28/2023
 
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis
FISHEL, MELISSA L⋅Flick, Matthew J⋅Han, Bumsoo and Wolberg, Alisa S
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 1U01HL143403-01), $818,452USD, 08/01/2018 -- 07/31/2023
2017
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
FISHEL, MELISSA L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA167291-05), $444,566USD, 01/01/2013 -- 12/31/2017
2016
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
FISHEL, MELISSA L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 4R01CA167291-04), $493,963USD, 01/01/2013 -- 12/31/2017
2015
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
FISHEL, MELISSA L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA167291-03), $493,963USD, 01/01/2013 -- 12/31/2015
2014
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
FISHEL, MELISSA L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA167291-02), $479,144USD, 01/01/2013 -- 12/31/2017
2013
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
FISHEL, MELISSA L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA167291-01A1), $493,963USD, 01/01/2013 -- 12/31/2017
2008
Chemosensitization of Pancreatic Tumors via Inhibition of a DNA BER Enzyme, Ape1
FISHEL, MELISSA L
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA122298-02), $181,800USD, 05/01/2007 -- 04/30/2010
2007
Chemosensitization of Pancreatic Tumors via Inhibition of a DNA BER Enzyme, Ape1
FISHEL, MELISSA L
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA122298-01A1), $151,500USD, 05/01/2007 -- 04/30/2009